Zonisamide-13C2,15N, CAS 1188265-58-8

Formulation: A solid

Formal Name: 1,2-benzisoxazole-3-13C-3-methane-13C-sulfonamide-15N

Purity: ≥95%

Formula Markup: C6[13C]2H8N[15N]O3S

Formula Weight: 215,2

Shelf life (days): 1460

CAS Number: 1188265-58-8

Notes: Zonisamide-13C2,15N is intended for use as an internal standard for the quantification of zonisamide (Item No. 24183) by GC- or LC-MS. Zonisamide is an antiepileptic agent.{41543} It selectively inhibits the repeated firing of sodium channels (IC50 = 2 μg/ml) in mouse embryo spinal cord neurons and inhibits spontaneous channel firing when used at concentrations greater than 10 μg/ml.{41545} In rat cerebral cortex neurons, zonisamide (1-1,000 μM) inhibits T-type calcium channels with a maximum reduction of 60% of the calcium current.{41546} Zonisamide inhibits H. pylori recombinant carbonic anhydrase (CA) and the human CA isoforms I, II, and V with Ki values of 218, 56, 35, and 21 nM, respectively.{33180,41544} In mice, it has anticonvulsant activity against maximal electroshock seizure (MES) and pentylenetetrazole-induced maximal, but not minimal, seizures (ED50s = 19.6, 9.3, and >500 mg/kg, respectively). Zonisamide (40 mg/kg, p.o.) prevents MPTP-induced decreases in the levels of dopamine (Item No. 21992), but not homovanillic acid (HVA; Item No. 27307) or dihydroxyphenyl acetic acid (DOPAC; Item No. 24912), and increases MPTP-induced decreases in the dopamine turnover rate in mouse striatum in a model of Parkinson's disease.{45492} Formulations containing zonisamide have been used in the treatment of partial seizures in adults with epilepsy.

• Artikelnummer: CAY28807
• Hersteller: Cayman Chemical
• Hersteller Artikelnummer: 28807-1
• Green Labware: Nein
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK
• Methode: GC-MS, LC-MS, Isotopenmarkierung